Kajalakshmy M. Phase Ii Trial Of Bevacizumab, Irinotecan, And Cetuximab In Recurrent Glioblastoma Multiforme: Efficacy, Safety And Clinical Outcomes. JRTDD 2022, 5, 788-792.